BACKGROUND: Cross-sectional studies show that white adipose tissue hypertrophy (few, large adipocytes), in contrast to hyperplasia (many, small adipocytes), associates with insulin resistance and increased risk of developing type 2 diabetes. We investigated if baseline adipose cellularity could predict improvements in insulin sensitivity following weight loss. METHODS: Plasma samples and subcutaneous abdominal adipose biopsies were examined in 100 overweight or obese individuals before and 10 weeks after a hypocaloric diet (7±3% weight loss) and in 61 obese subjects before and 2 years after gastric by-pass surgery (33±9% weight loss). The degree of adipose tissue hypertrophy or hyperplasia (termed the morphology value) in each individual was calculated on the basis of the relationship between fat cell volume and total fat mass. Insulin sensitivity was determined by homeostasis model assessment-estimated insulin resistance (HOMAIR). RESULTS: In both cohorts at baseline, subjects with hypertrophy displayed significantly higher fasting plasma insulin and HOMAIR values than subjects with hyperplasia (P<0.0001), despite similar total fat mass. Plasma insulin and HOMAIR were normalized in both cohorts following weight loss. The improvement (delta insulin or delta HOMAIR) was more pronounced in individuals with hypertrophy, irrespective of whether adipose morphology was used as a continuous (P=0.0002-0.027) or nominal variable (P=0.002-0.047). Absolute adipocyte size associated (although weaker than morphology) with HOMAIR improvement only in the surgery cohort. Anthropometric measures at baseline (fat mass, body mass index, waist-to-hip ratio or waist circumference) showed no significant association with delta insulin or delta HOMAIR. CONCLUSIONS: In contrast to anthropometric variables or fat cell size, subcutaneous adipose morphology predicts improvement in insulin sensitivity following both moderate and pronounced weight loss in overweight/obese subjects.
BACKGROUND: Cross-sectional studies show that white adipose tissue hypertrophy (few, large adipocytes), in contrast to hyperplasia (many, small adipocytes), associates with insulin resistance and increased risk of developing type 2 diabetes. We investigated if baseline adipose cellularity could predict improvements in insulin sensitivity following weight loss. METHODS: Plasma samples and subcutaneous abdominal adipose biopsies were examined in 100 overweight or obese individuals before and 10 weeks after a hypocaloric diet (7±3% weight loss) and in 61 obese subjects before and 2 years after gastric by-pass surgery (33±9% weight loss). The degree of adipose tissue hypertrophy or hyperplasia (termed the morphology value) in each individual was calculated on the basis of the relationship between fat cell volume and total fat mass. Insulin sensitivity was determined by homeostasis model assessment-estimated insulin resistance (HOMAIR). RESULTS: In both cohorts at baseline, subjects with hypertrophy displayed significantly higher fasting plasma insulin and HOMAIR values than subjects with hyperplasia (P<0.0001), despite similar total fat mass. Plasma insulin and HOMAIR were normalized in both cohorts following weight loss. The improvement (delta insulin or delta HOMAIR) was more pronounced in individuals with hypertrophy, irrespective of whether adipose morphology was used as a continuous (P=0.0002-0.027) or nominal variable (P=0.002-0.047). Absolute adipocyte size associated (although weaker than morphology) with HOMAIR improvement only in the surgery cohort. Anthropometric measures at baseline (fat mass, body mass index, waist-to-hip ratio or waist circumference) showed no significant association with delta insulin or delta HOMAIR. CONCLUSIONS: In contrast to anthropometric variables or fat cell size, subcutaneous adipose morphology predicts improvement in insulin sensitivity following both moderate and pronounced weight loss in overweight/obese subjects.
Authors: A Katsuki; Y Sumida; E C Gabazza; S Murashima; M Furuta; R Araki-Sasaki; Y Hori; Y Yano; Y Adachi Journal: Diabetes Care Date: 2001-02 Impact factor: 19.112
Authors: Erik Arner; Pål O Westermark; Kirsty L Spalding; Tom Britton; Mikael Rydén; Jonas Frisén; Samuel Bernard; Peter Arner Journal: Diabetes Date: 2009-10-21 Impact factor: 9.461
Authors: Lindsey A Muir; Christopher K Neeley; Kevin A Meyer; Nicki A Baker; Alice M Brosius; Alexandra R Washabaugh; Oliver A Varban; Jonathan F Finks; Brian F Zamarron; Carmen G Flesher; Joshua S Chang; Jennifer B DelProposto; Lynn Geletka; Gabriel Martinez-Santibanez; Niko Kaciroti; Carey N Lumeng; Robert W O'Rourke Journal: Obesity (Silver Spring) Date: 2016-03 Impact factor: 5.002
Authors: Lindsey A Muir; Nicki A Baker; Alexandra R Washabaugh; Christopher K Neeley; Carmen G Flesher; Jennifer B DelProposto; Lynn M Geletka; Amir A Ghaferi; Jonathan F Finks; Kanakadurga Singer; Oliver A Varban; Carey N Lumeng; Robert W O'Rourke Journal: Adipocyte Date: 2017-01-27 Impact factor: 4.534
Authors: Cheehoon Ahn; Benjamin J Ryan; Michael W Schleh; Pallavi Varshney; Alison C Ludzki; Jenna B Gillen; Douglas W Van Pelt; Lisa M Pitchford; Suzette M Howton; Thomas Rode; Scott L Hummel; Charles F Burant; Jonathan P Little; Jeffrey F Horowitz Journal: J Physiol Date: 2022-03-20 Impact factor: 6.228
Authors: Juan R Acosta; Iyadh Douagi; Daniel P Andersson; Jesper Bäckdahl; Mikael Rydén; Peter Arner; Jurga Laurencikiene Journal: Diabetologia Date: 2015-11-25 Impact factor: 10.122
Authors: Natalia Moreno-Castellanos; Rocío Guzmán-Ruiz; David A Cano; Ainara Madrazo-Atutxa; Juan R Peinado; Jose L Pereira-Cunill; Pedro Pablo García-Luna; Salvador Morales-Conde; Maria Socas-Macias; Rafael Vázquez-Martínez; Alfonso Leal-Cerro; María M Malagón Journal: Obes Surg Date: 2016-08 Impact factor: 4.129